Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Announces Earnings Results

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) announced its quarterly earnings data on Wednesday. The company reported $0.01 earnings per share for the quarter, FiscalAI reports. The company had revenue of $3.57 million during the quarter.

Hong Kong Pharma Digital Technology Stock Performance

HKPD stock traded up $0.04 on Wednesday, reaching $0.66. The company’s stock had a trading volume of 24,225 shares, compared to its average volume of 41,304. The business has a fifty day simple moving average of $0.74 and a two-hundred day simple moving average of $0.99. Hong Kong Pharma Digital Technology has a 12-month low of $0.58 and a 12-month high of $2.76.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hong Kong Pharma Digital Technology in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. purchased a new position in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned 0.39% of Hong Kong Pharma Digital Technology as of its most recent SEC filing.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.